Please assess the completion status of the following clinical trial:

Trial Title: Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with established adult rheumatoid arthritis currently on Methotrexate for at least 3 months~Exclusion Criteria:~* All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment~* Previous clinical trials participation and previous biological therapy that could interfere with the results of the present clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 400 mg and placebo (Type: ACTIVE_COMPARATOR): 400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
- Certolizumab pegol 200 mg and placebo (Type: EXPERIMENTAL): 200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered as two injections every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).